|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
September 2004FeaturesClinical How Biologics Are DifferentIn all respects, biotechnology is turning medicine inside out, from diagnostics and therapeutics to issues of utilization, patient selection, and cost. Thomas Morrow, MD, offers a primer on how biologic therapies’ unique characteristics influence production, administration, and efficacy – and purchasers’ decisions. Diagnostics To Test or Not To Test?Attempting to justify the price of a genetic assay raises questions about the affordability of not testing. Economic Injectables: Clinical Applications and Financial EffectsBiologic therapies don’t fit traditional pharmacy benefit designs. The authors model the effects on all stakeholders of new plan-design changes. Business The Subcontinental SurgeIndia’s biotech industry is poised to explode, with top-notch facilities, motivated workers, and a large pool of study subjects. Will India play by the rules? Specialty Pharmacy Specialty Pharmacies Tackle Top 5 Employer ConcernsBiotechnology Healthcare surveyed specialty pharmacies and found distribution, adherence, and cost among purchasers’ biggest sources of anxiety. Leading Edge Creating Therapeutic Proteins from Bioengineered SystemsThink of a field of lettuce as a protein-production lab – and the implications of that. It’s an idea that merits support DepartmentsOpeners What Made Dr. Crick Tick?
Michael D. Dalzell Editorial Washington MusingsDavid B. Nash, MD, MBA, muses on a little-known aspect of Medicare reform. Drugs & DiagnosticsThoughts on the FDA’s guidance on pharmacogenomics. Also, approvals, denials, and clinical trials. Biotech BusinessMost privately funded clinical trials go unregistered. The FDA wants that to end. Discourse: Biodefense Project Bioshield: Pot o’ Gold, But Money Misdirected?Biodefense is big business, with money up for grabs for blue-sky research. In the Pipeline Mode of administration a factor in biologic drug costsMode of delivery as a cost factor. |
|||||